DK2705144T4 - Polypeptid - Google Patents
Polypeptid Download PDFInfo
- Publication number
- DK2705144T4 DK2705144T4 DK11720345.5T DK11720345T DK2705144T4 DK 2705144 T4 DK2705144 T4 DK 2705144T4 DK 11720345 T DK11720345 T DK 11720345T DK 2705144 T4 DK2705144 T4 DK 2705144T4
- Authority
- DK
- Denmark
- Prior art keywords
- polypeptide
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2462—Lysozyme (3.2.1.17)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56938—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/NL2011/050307 WO2012150858A1 (en) | 2011-05-04 | 2011-05-04 | A polypeptide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK2705144T3 DK2705144T3 (da) | 2016-09-05 |
| DK2705144T4 true DK2705144T4 (da) | 2019-10-21 |
Family
ID=44626456
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11720345.5T DK2705144T4 (da) | 2011-05-04 | 2011-05-04 | Polypeptid |
| DK16172568.4T DK3085777T3 (da) | 2011-05-04 | 2011-05-04 | Polypeptid |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16172568.4T DK3085777T3 (da) | 2011-05-04 | 2011-05-04 | Polypeptid |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US9382298B2 (da) |
| EP (2) | EP2705144B2 (da) |
| JP (1) | JP6261086B2 (da) |
| KR (1) | KR101911114B1 (da) |
| CN (2) | CN108192902A (da) |
| AU (1) | AU2011367262B2 (da) |
| BR (1) | BR112013028251B1 (da) |
| CA (1) | CA2834924C (da) |
| DK (2) | DK2705144T4 (da) |
| ES (2) | ES2768777T3 (da) |
| IL (1) | IL229247B (da) |
| PL (2) | PL2705144T3 (da) |
| SG (1) | SG194776A1 (da) |
| WO (1) | WO2012150858A1 (da) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9206411B2 (en) * | 2012-06-13 | 2015-12-08 | The United States Of America, As Represented By The Secretary Of Agriculture | Staphylococcal Phage2638A endolysin amidase domain is lytic for Staphylococcus aureus |
| AU2014287845B2 (en) * | 2013-07-11 | 2019-11-14 | Micreos Human Health B.V. | Combination treatment for atopic dermatitis |
| EP3143137A4 (en) * | 2014-05-14 | 2017-11-15 | Trustees of Dartmouth College | Deimmunized lysostaphin and methods of use |
| EP3268023B1 (en) * | 2015-03-12 | 2021-08-18 | Micreos Human Health B.V. | Combination of bactericidal agent with a lysosomotropic alkalinising agent for the treatment of a bacterial infection |
| NO3144387T3 (da) * | 2015-09-15 | 2018-08-11 | ||
| EP3692149B1 (en) | 2017-10-06 | 2023-01-04 | Micreos Human Health B.V. | Treatment of a condition associated with infection with an oncogenic bacterium |
| BR112020017219A2 (pt) * | 2018-02-26 | 2020-12-22 | Contrafect Corporation | Lisinas plyss2 modificadas e usos das mesmas |
| JP7454211B2 (ja) * | 2020-01-20 | 2024-03-22 | 日本全薬工業株式会社 | バクテリオファージ由来エンドライシン |
| JP2023518377A (ja) | 2020-03-19 | 2023-05-01 | マイクレオス ヒューマン ヘルス ビー．ブイ． | 安定化された対象となるタンパク質 |
| IL297430A (en) * | 2020-04-20 | 2022-12-01 | Micreos Human Health Bv | Chimeric endolysin polypeptide |
| US20240392275A1 (en) * | 2021-09-22 | 2024-11-28 | Biomedit, Llc | Lysostaphin variants and methods of use thereof |
| CN116732013B (zh) * | 2022-03-01 | 2025-07-25 | 百葵锐(深圳)生物科技有限公司 | 具有抗菌活性的细胞壁降解酶 |
| WO2024241070A1 (en) | 2023-05-22 | 2024-11-28 | L'oreal | Cosmetic composition comprising an endolysin and a polyvinyl alcohol |
| FR3149209B1 (fr) | 2023-06-02 | 2026-04-03 | Oreal | Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et un alcool aromatique |
| FR3152395A1 (fr) | 2023-08-28 | 2025-03-07 | L'oreal | Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et la 4-hydroxyacetophenone |
| EP4719330A1 (en) | 2023-06-02 | 2026-04-08 | L'oreal | Cosmetic composition comprising an endolysin derived from a staphylococcus aureus phage and an aromatic alcohol |
| FR3149205B1 (fr) | 2023-06-02 | 2026-04-24 | Oreal | Composition cosmétique comprenant une endolysine et un agent de charge organique |
| FR3149208B1 (fr) | 2023-06-02 | 2026-03-20 | Oreal | Composition cosmétique, notamment aqueuse, comprenant une endolysine et un pullulane |
| FR3149202B1 (fr) | 2023-06-02 | 2026-04-10 | Oreal | Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et une huile. |
| FR3149203B1 (fr) | 2023-06-02 | 2026-03-13 | Oreal | Composition anhydre comprenant une endolysine et de l’hydroxypropylmethylcellulose et/ou du pullulane |
| FR3149207B1 (fr) | 2023-06-02 | 2026-03-13 | Oreal | Composition cosmétique comprenant une endolysine et un composé de formule (I) |
| FR3149204B1 (fr) | 2023-06-02 | 2026-02-13 | Oreal | Composition cosmétique comprenant une endolysine et un tensioactif non ionique comprenant un résidu carbohydrate |
| FR3149206B1 (fr) | 2023-06-02 | 2026-03-13 | Oreal | Composition cosmétique aqueuse comprenant une endolysine et du tréhalose |
| FR3149201B1 (fr) | 2023-06-02 | 2026-04-03 | Oreal | Composition cosmétique anhydre comprenant une endolysine dérivée de phage de Staphylococcus aureus et du mannitol. |
| JPWO2025005276A1 (da) | 2023-06-30 | 2025-01-02 | ||
| FR3152393B1 (fr) | 2023-08-28 | 2026-04-24 | Oreal | Composition cosmétique comprenant une endolysine dérivée d’un phage de Staphylococcus aureus et une charge minérale |
| FR3152394B1 (fr) | 2023-08-28 | 2026-04-24 | Oreal | Composition cosmétique comprenant une endolysine et des particules d’aérogel de silice hydrophobe |
| FR3152396A1 (fr) | 2023-08-28 | 2025-03-07 | L'oreal | Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et un polyhydroxyalcane |
| WO2025093666A1 (en) | 2023-11-01 | 2025-05-08 | University Of Copenhagen | Treatment of lymphoma |
| FR3160704A1 (fr) * | 2024-03-29 | 2025-10-03 | Vetophage | Nouvelle endolysine de phage et ses utilisations |
| PL449075A1 (pl) * | 2024-06-29 | 2026-01-05 | Instytut Medycyny Doświadczalnej I Klinicznej Im. M. Mossakowskiego Polskiej Akademii Nauk | Rekombinowane białko hydrolazy peptydoglikanowej o właściwościach przeciwbakteryjnych, kompozycje je zawierające, ich zastosowania oraz sposoby je wykorzystujące |
| WO2026052743A1 (en) | 2024-09-04 | 2026-03-12 | Micreos Human Health B.V. | Reduction of trans-epidermal water loss by a polypeptide with antibacterial properties |
| CN119799686B (zh) * | 2024-12-27 | 2026-04-21 | 杭州微新生物科技有限公司 | 一种靶向鸡肠球菌的抗菌蛋白及其制备方法与应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009024327A2 (en) * | 2007-08-22 | 2009-02-26 | Profos Ag | New proteins for use in human and animal staphylococcus infections |
| CA2729160C (en) * | 2008-07-03 | 2017-11-14 | The Rockefeller University | A chimeric bacteriophage lysin with activity against staphylococci bacteria |
| WO2010011960A2 (en) | 2008-07-24 | 2010-01-28 | The United State Of America, As Represented By The Secretary Of Agriculture | Triple acting antimicrobials that are refractory to resistance development |
| EP2157100A1 (en) * | 2008-08-19 | 2010-02-24 | Profos AG | Artificial peptidoglycan lysing enzymes and peptidoglycan binding proteins |
| US9534223B2 (en) * | 2010-04-27 | 2017-01-03 | Lysando Ag | Method of reducing biofilms |
| EP2702070B1 (en) * | 2011-04-27 | 2015-09-30 | Lysando AG | New antimicrobial agents |
-
2011
- 2011-05-04 DK DK11720345.5T patent/DK2705144T4/da active
- 2011-05-04 US US14/115,609 patent/US9382298B2/en active Active
- 2011-05-04 CA CA2834924A patent/CA2834924C/en active Active
- 2011-05-04 PL PL11720345.5T patent/PL2705144T3/pl unknown
- 2011-05-04 AU AU2011367262A patent/AU2011367262B2/en active Active
- 2011-05-04 CN CN201711457491.2A patent/CN108192902A/zh active Pending
- 2011-05-04 WO PCT/NL2011/050307 patent/WO2012150858A1/en not_active Ceased
- 2011-05-04 JP JP2014509259A patent/JP6261086B2/ja active Active
- 2011-05-04 ES ES16172568T patent/ES2768777T3/es active Active
- 2011-05-04 EP EP11720345.5A patent/EP2705144B2/en active Active
- 2011-05-04 ES ES11720345T patent/ES2589784T5/es active Active
- 2011-05-04 CN CN201180072127.9A patent/CN103703127A/zh active Pending
- 2011-05-04 BR BR112013028251-7A patent/BR112013028251B1/pt active IP Right Grant
- 2011-05-04 SG SG2013081633A patent/SG194776A1/en unknown
- 2011-05-04 KR KR1020137032135A patent/KR101911114B1/ko active Active
- 2011-05-04 EP EP16172568.4A patent/EP3085777B1/en not_active Revoked
- 2011-05-04 PL PL16172568T patent/PL3085777T3/pl unknown
- 2011-05-04 DK DK16172568.4T patent/DK3085777T3/da active
-
2013
- 2013-11-04 IL IL229247A patent/IL229247B/en active IP Right Grant
-
2016
- 2016-06-02 US US15/171,448 patent/US10174300B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2705144A1 (en) | 2014-03-12 |
| ES2768777T3 (es) | 2020-06-23 |
| WO2012150858A1 (en) | 2012-11-08 |
| IL229247A0 (en) | 2014-01-30 |
| CN108192902A (zh) | 2018-06-22 |
| PL2705144T3 (pl) | 2016-12-30 |
| DK3085777T3 (da) | 2020-02-03 |
| US20160369255A1 (en) | 2016-12-22 |
| AU2011367262A1 (en) | 2013-11-21 |
| US9382298B2 (en) | 2016-07-05 |
| PL3085777T3 (pl) | 2020-05-18 |
| AU2011367262B2 (en) | 2016-11-03 |
| CA2834924C (en) | 2022-08-16 |
| KR20140066976A (ko) | 2014-06-03 |
| EP3085777A1 (en) | 2016-10-26 |
| US20140127168A1 (en) | 2014-05-08 |
| CN103703127A (zh) | 2014-04-02 |
| EP2705144B1 (en) | 2016-06-08 |
| IL229247B (en) | 2019-03-31 |
| DK2705144T3 (da) | 2016-09-05 |
| BR112013028251B1 (pt) | 2021-04-06 |
| JP2014519815A (ja) | 2014-08-21 |
| BR112013028251A2 (pt) | 2017-01-17 |
| EP3085777B1 (en) | 2019-11-06 |
| US10174300B2 (en) | 2019-01-08 |
| CA2834924A1 (en) | 2012-11-08 |
| SG194776A1 (en) | 2013-12-30 |
| ES2589784T5 (es) | 2020-04-21 |
| EP2705144B2 (en) | 2019-08-28 |
| HK1195791A1 (zh) | 2014-11-21 |
| KR101911114B1 (ko) | 2018-10-23 |
| JP6261086B2 (ja) | 2018-01-17 |
| ES2589784T3 (es) | 2016-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3085777T3 (da) | Polypeptid | |
| DK2728002T3 (da) | Heterodimeriseret polypeptid | |
| DK2940135T5 (da) | Heterodimeriseret polypeptid | |
| BR112014004902A2 (pt) | peptídeos | |
| CO7020866A2 (es) | Péptidos terapéuticos | |
| IL232247A0 (en) | Polypeptide constructs and uses thereof | |
| BR112013017629A2 (pt) | laminina-521 recombinante | |
| EP2839019A4 (en) | CD3 BINDING POLYPEPTIDES | |
| CO6900146A2 (es) | Imidazopiridazinas sustituidas con amino | |
| EP2699293A4 (en) | SELF-INJECTOR APPARATUS | |
| BR112013020613A2 (pt) | autoinjetor | |
| DK2797616T3 (da) | Celle-penetrerende peptider | |
| EP2791034A4 (en) | Transport apparatus | |
| CO6862104A2 (es) | Inmunotoxina recombinante dirigida a la mesotelina | |
| HUE040326T2 (hu) | Mutáns interleukon-2 polipeptidek | |
| FI20116181L (fi) | Uusia terapeuttisia vektoreita | |
| DK3384944T3 (da) | Autoinjektor | |
| SG11201400432VA (en) | Polypeptide vaccine | |
| FR2977490B1 (fr) | Composition photoprotectrice | |
| EP2794701A4 (en) | A peptide-hydrogel composite | |
| PL2663506T3 (pl) | Zamknięcie | |
| IL231616A0 (en) | Tropicalizing agent | |
| FI20116212L (fi) | Polypeptidi | |
| FR2988733B1 (fr) | Microorganisme recombinant | |
| BR112013029769A2 (pt) | levedura recombinante |